ObsEva Announces Plans to Conduct Initial Public Offering in the United States

GENEVA, Oct. 17, 2016 -- ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that the Company plans to conduct an initial public offering in the United States.

This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

The timing and the terms of this initial public offering have not yet been determined.

Press Release: http://hugin.info/157613/R/2049240/766325.pdf 

Media Contact:

Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526

Company Contact:

Delphine Renaud
ObsEva, CEO Office
[email protected]
+41 22 552 1550